63 results about "Ketorolac Tromethamine" patented technology

Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation or insertion at a site associated with pain or discomfort upon implantation or insertion. In many embodiments, the therapeutic will be selected from at least one of (i) ketorolac and pharmaceutically acceptable salts thereof (e.g., ketorolac tromethamine) and (ii) 4-diethylamino-2-butynylphenylcyclohexyl glycolate and pharmaceutically acceptable salts thereof (e.g., oxybutynin chloride). Also provided are uses for the implantable or insertable medical devices, which uses comprise reducing pain or discomfort accompanying the implantation or insertion of such devices. Further uses may comprise reducing microbial buildup along the device. Methods for manufacturing implantable or insertable medical devices are also provided.

Disclosed is ketorolac tromethamine, which is a pyrrole acid derivative developed by the Syntex company in the U.S. The invention can effectively inhibit prostaglandin (PG) from synthesizing with functions of analgesia, anti-inflammation, antipyresis and inhibiting the platelets from aggregating. The invention provides a preparation method of ketorolac tromethamine injection, which well improves the stability and the clarity of the preparation with stable process.

The invention discloses a ketorolac tromethamine injection characterized by being prepared from the following components in percentage by weight: 0.1-15 percent of ketorolac tromethamine, 0.01-10 percent of buffering agent and 0.001-5 percent of pH value regulator. In the invention, because a traditional menstruum, such as ethanol is replaced by a phosphate buffer solution, the ketorolac tromethamine injection with good stability, less irritation, safety and more convenience is obtained so as to improve the medicament compliance of patients and the clinical medication convenience.

The present invention relates to a non-steroidal anti-inflammatory drug of ketorolac tromethamine salt, which has the functions of strong acesodyne, moderate anti-inflammation and antipyresis. The present invention applies a synthesis route preparing the compound ketorolac tromethamine salt, the technique applies an one-pot method, the reaction process from 2-benzoyl pyrrole to the ketorolac tromethamine salt can be continuously carried out, extraction and purification are not needed, materials can be easily obtained, labor intensity is reduced, the operational environment is improved, the cost of industrialized production is greatly reduced, environmental pollution is reduced, the loss of materials and products is reduced, and the yield rate is increased.

Ketorolac tromethamine is a new type of non-steroidal analgesic and anti-inflammatory drug with strong analgesic effect, which can be administered orally or by injection. It is mainly used to relieve moderate to severe postoperative pain, and Acute renal colic related to trauma, visceral pain related to cancer, anti-inflammatory of local inflammation, etc., the present invention provides a preparation method of ketorolac tromethamine freeze-dried powder preparation, which greatly improves the stability of the main drug, It not only overcomes the shortcoming of slow onset of oral administration, but more importantly, overcomes the problems of unstable main drug of liquid injection and unstable process in actual production.

The invention provides a ketorolac tromethamine injection capable of reducing irritation and free of an organic solvent. By using a tromethamine-acidifying agent buffer system is used as a protectiveagent, adverse effects of ethanol and monopotassium phosphate on a packing material and severe irritation at an injection part in the prior art are avoided. The production process is simple and controllable, the physicochemical property of the liquid medicine is stable, and the medication safety and compliance of patients can be improved.

The invention discloses an HPLC (high performance liquid chromatography) detection method of ketorolac tromethamine or ketorolac tromethamine or/and impurities in ketorolac tromethamine preparation; HPLC is used to detect a solution under detection, and qualitatively or quantitatively determining according to chromatographic results. The HPLC impurity detection method for ketorolac tromethamine bulk pharmaceutical chemicals and related impurities in injections has the advantages that optimizing and modifying are performed in the aspects of detection wavelength and mobile phase system determining, test solution concentration screening and the like, the method is verified in the aspects of system applicability, degrading specificity, detection limit and quantitative limit, linearity and range, precision, accuracy, solution stability, method durability and the like, and the results show that the method has good capacity of detecting impurities.

The invention discloses a medicine composition for treating constipation and/or haemorrhoids and belongs to the field of medicines. Aiming at providing a medicine for treating constipation and/or haemorrhoids with a definite curative effect and specific ingredients, the invention discloses a medicine composition used for treating haemorrhoids, the medicine composition used for treating the haemorrhoids contains two ingredients, namely lubiprostone and ketorolac tromethamine, and the ratio of lubiprostone to ketorolac tromethamine is (0.02-10):1, preferably (0.1-5):1, and more preferably (0.5-2):1. A large number of experimental studies show that the medicine composition has an obvious treatment effect on anorectal diseases such as the haemorrhoids.

The invention provides a ketorolac tromethamine nasal spray. A spraying device comprises a spraying bottle and a spraying head, and is characterized in that the spraying bottle comprises a casing (1) and a liner (2) with the volume of 1.5 ml; the liner of the spraying bottle is in a shape of a cylinder, the combination of a cylinder and a cone, or the combination of a cylinder, a cone and a cylinder with a smaller diameter ; the casing of the spraying bottle has the same appearance, size and connector part as those of a conventional 10 ml spray sold in the market; and the spraying head adopts a praying head of the conventional 10 ml spray sold in the market. The ketorolac tromethamine nasal spray has the advantages of few residues, high safety and multiple effective spraying times, the production cost can be reduced, and the medicine waste is prevented.

The invention provides a preparation method of ketorolac tromethamine. 5-benzoyl-2, 3-dihydro-1H-dilazine-1 and 1-diethyl azodicarboxylate are the starting materials and are prepared into salt by alkaline hydrolysis and acidification when reducers exist, and finally, the salt is prepared into ketorolac tromethamine. The method does not need complicated decarboxylation process, and effectively solves the problems of low purity, poor color and the like caused by the oxidizability of ketorolac. The invention has the advantages of simple operation, high yield and high purity (the total yield in two steps reaches 95% and the purity reaches more than 99.9%); thus, the preparation method is suitable for large-scale commercial process.

Provided is a medical kit with all the necessary components for a medical practitioner in the office practice setting to inject a variety of anesthetics. The kits can comprise a holder, such as a box, and active pharmaceutical ingredients (API), with each API placed in a separate container in a form that is ready for injection, the API selected from the group consisting of: a. lidocaine hydrochloride and triamcinolone acetonide with or without a separate container of ammonia; b. bupivacaine hydrochloride (HCl) and lidocaine hydrochloride (HCl), and optionally one or more of triamcinolone acetonide, methylprednisolone acetate, or dexamethasone sodium; c. bupivacaine hydrochloride (HCl) and one or more of triamcinolone acetonide or methylprednisolone acetate; d. Methylprednnisolone acetate and lidocaine hydrochloride (HCl), and optionally bupivacaine hydrochloride (HCl); e. methylprednisolone acetate and lidocaine hydrochloride (HCl), and bupivacaine hydrochloride (HCl); f. lidocaine hydrochloride, triamcinolone acetonide, and ammonia; g. bupivacaine hydrochloride or lidocaine HCl, and betamethasone sodium phosphate and betamethasone acetate; h. bupivacaine hydrochloride or lidocaine HCl, and dexamethasone sodium phosphate; i. ketorolac tromethamine, lidocaine HCl, and optionally bupivacaine hydrochloride; and j. one or more of dexamethasone sodium.

The hemorrhoids are more suitable to be treated conservatively by medicaments mainly. The invention discloses a medicinal composition for treating hemorrhoids, which comprises two components, i.e. pentoxifyllinum and ketorolac tromethamine, wherein the ratio of pentoxifyllinum to ketorolac tromethamine is 0.02-10:1, preferably 0.1-5:1, more preferably 0.5-2:1. A mass of experimental studies show that the medicinal composition has obvious treatment effect on anorectal diseases, such as hemorrhoids and the like.

The invention discloses a method for researching an abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets and a pharmaceutical composition comprising the Xinhuang tablets. The method for researching the abirritation mechanism comprises the following steps of preparing a Xinhuang tablet sample and an indometacin sample in a weight ratio of 95:2, establishing a living acetic acid writhing reaction model and a living planta reaction model to evaluate the drug treatment effects and the synergic index of the Chinese herbal medicinal ingredients of the Xinhuang tablets and indometacin, and establishing a naloxone occlusion reaction model to evaluate the influence of occlusion on the analgesic effect. Based on the research on the mechanism of action, and in order to improve the treatment effect for analgesia, the invention also provides an analgesic composition which is composed of the Xinhuang tablets and ketorolac tromethamine. The method is used for measuring the abirritation mechanism of the Chinese herbal medicinal ingredients of the Xinhuang tablets, is simple and clear; applicable effective drugs can be selected from the known compound medicines by the pharmacological research method.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

The invention provides a ketorolac tromethamine injection. The packing volume of the injection is 0.5ml, and the content of ethanol is 10-18 percent (W/V). Furthermore, the preparation method is improved. Compared with the prior art, the injection provided by the invention has the advantages that the usage of the ethanol is reduced, the stability of the injection is improved, and the white spots cannot be separated out from the medicine; the administration safety can be improved because propylene glycol, phosphate and other additional components are not added; the process is simple and feasible, and is suitable for industrial production.

The invention belongs to the field of medicine preparations and relates to a nasal-delivery temperature-sensitive in-situ gel sustained-release preparation comprising ketorolac tromethamine and a preparation method thereof. The preparation is composed of poloxamer, carrageenan and ketorolac tromethamine in effective dose. The preparation integrates reverse-phase gelatinization property of the poloxamer and the property that the carrageenan can significantly improve erosion of the temperature-sensitive gel, and improves retention effect of the poloxamer gel in nasal cavity and improves absorption of the ketorolac tromethamine. The preparation is improved in bioavailability of the ketorolac tromethamine through nasal delivery and improves patient compliance.

The invention discloses an inner liner type medicine bottle for ketorolac tromethamine spray. The inner liner type medicine bottle for the ketorolac tromethamine spray comprises a bottle neck (3), an outer bottle (1) and an inner liner bottle (2) which is arranged inside the outer bottle (1). The inner liner type medicine bottle for the ketorolac tromethamine spray is characterized in that the bottle neck (3) extends to the interior of the bottle body of the outer bottle (1) to form the inner liner bottle (2) in a sealing mode, and a plurality of outer threads (4) are formed in the outer surface of the bottle neck (3). The inner liner type medicine bottle for the ketorolac tromethamine spray is light in weight, and solves the filling problem of small size liquid medicament, and simultaneously improves safety of medicament transportation and stability of long-time placement of the medicament.

The present invention relates to a pharmaceutical composition comprising the synergistic combination of a non-steroidal anti-inflammatory drug (NSAID), such as the active ingredient s-ketorolac tromethamine, and an opioid agent, such as the active ingredient tramadol chlorhydrate, which ingredients are formulated with pharmaceutically acceptable excipients. The composition is used for the control and treatment of mild and/or moderate and/or severe pain.

The invention provides a ketorolac tromethamine capsule and a preparation method thereof, which belong to the technical field of medicine preparations. The ketorolac tromethamine capsule is prepared by the following steps: making ketorolac tromethamine into slow-release coated micropills and ordinary micropills; and then, uniformly and proportionally mixing the two kinds of micropills to be put into capsule cases. After the capsule enters the gastrointestinal tract, the ordinary micropills fast release medicine for taking effect, and the slow-release micropills persistently release the medicine through regulating the thickness and the materials of coated films, so the peak valley phenomenon of ordinary capsules is avoided, good release curves and repeatability can be obtained, the occurrence of untoward effects of the medicine is reduced, in addition, the medicine using times are reduced, and the adaptability of patients is improved. The preparation method of the capsule has the advantages of simple process and good controllability, and is suitable for industrial production.

A multimodal anti-emetic anesthetic/analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free/sparing anesthetic/analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics/analgesics. The formulation is administered to a mammal in need of anesthesia/analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.

The invention relates to an externally applied ointment of ketorolac tromethamine and its preparation method, wherein the ointment comprises 1-5 wt% of ketorolac tromethamine, 0.5-95 wt% of ointment matrix, 0.2-2 wt% of bactericidal agent, 1-4 wt% of penetration enhancer, 1-2 wt% of propylene glycol and aqueous medium. The preparing process comprises (1) preparing ketorolac tromethamine soup, (2) preparing blank ointment, (3) preparing the ointment.